India IPO Pipeline SEBI Regulatory Filings — April 10, 2026

Post-IPO Reg 74(5) compliance certificate dated Apr 1 confirms timely demat processing within timelines, reducing post-listing regulatory risks

Acquired 775,744 shares at Rs.241/share (Rs.18.69 Cr) to reach 100% stake from 99.42%, following prior buys, enhancing sub control

Wholly-owned L&T RPL buying 100% (58,23,425 shares) in IGSL for ₹1,123 Cr, leveraging Gurugram land for residential expansion despite NIL turnover FY22-25

Assigned top-tier 'Care Edge - ESG 1+' rating for leadership in ESG disclosures/policies/performance, boosting investor appeal

BSE in-principle approval for listing 5L ESOP shares (Rs.2 FV, ISIN INE0WO601020), conditional on allotment/ compliances, signaling employee incentives post-IPO

CRISIL upgrade to AA+/Stable (first since 2017) post-IHC promoter acquisition via preferential issue, reflecting strong capitalization and growth pivot

Nexus funds' combined holding stable pre-Jun25 but sold 24M shares across two tranches (Jun26'25 & Apr8'26), no encumbrances but sharp dilution

Board meeting scheduled Apr28'26 for FY26 audited results and dividend recommendation, typical pre-earnings catalyst

Received NCLT order dated Mar26'26 approving meetings for demerger/amalgamation with Apollo Healthco/Keimed/Healthtech, dispensing several creditor meetings

Short-term CP/NCD ratings reaffirmed A1+, supporting liquidity amid promoter change

No regulatory approvals needed for IGSL acquisition, on track for completion by Apr15'26, fast-tracking land bank expansion

ESG rating pursuant to Reg30 highlights best-in-class risk management, potential for premium valuations

Nexus Opportunity & Ventures III sold 24M shares (3.26M + 20.74M), dropping combined holding from 6.76% (50.58M shares) to 3.55% (26.58M), signaling reduced conviction

Pre-transaction: Nexus Ventures held 5.86% (43.85M), post: 3.46% diluted; open market sales in Apr8'26 tranche amid market volatility

Target IGSL reported NIL turnover FY22-23/23-24/24-25, potential integration risks in realty development despite strategic land value

BSE approval subject to post-allotment notifications, fee payments, and compliances; delay risks in ESOP liquidity

NCLT meetings required for select creditors (secured/unsecured of Apollo/Healthco/Keimed), potential objections despite dispensations

IHC as new promoter post-Oct'25 agreement and open offer; execution risks if subscription terms unmet

Reg74(5) cert confirms processing but any mutilated/bad shares could flag operational issues

Upcoming Apr28 board for FY26 results; historical dividend trends to watch for cuts amid auto sector pressures

Large 24M share divestment over 9 months (Jun'25-Apr'26) without pledges, but volume may pressure stock

₹1,123 Cr for 58L shares (implied ~₹1,929/share) on NIL revenue base, overpayment risk if land development delays

Full 100% consolidation in health sub at Rs.241/share post prior IFC buys, unlocks synergies in lifestyle/health segment

₹1,123 Cr IGSL acquisition adds Gurugram residential pipeline (inc. 1993 entity), no approvals needed, close by Apr15'26

AA+/Stable + A1+ reaffirmation post-IHC stake, positions for growth funding/tighter spreads vs peers

In-principle BSE approval for 5L shares, enhances employee retention/liquidity, positive for post-IPO stability

'ESG 1+' rating differentiates in sustainable investing, potential inflows amid global ESG mandates

NCLT greenlight for meetings advances Apollo Healthco/Keimed/Healthtech integration, value unlock via focused entities

Timely Reg74(5) filing post-listing (scrip 530853) clears demat hurdles, attractive for short-term momentum plays

Apr28 board for FY26 results/dividend; track record of payouts offers yield opportunity if maintained

Robust buffers post-upgrade support pivot to growth, undervalued vs AA+ peers

Strategic buy despite NIL turnover positions for Haryana residential boom, relative value vs land-scarce developers

Apollo Hospitals' dual filings show 100% sub control (Rs.18.69 Cr buyout) + NCLT scheme progress, 2/9 filings signal M&A/de-merger for efficiency [POSITIVE IMPLICATIONS: Margin expansion via synergies]

L&T RPL's ₹1,123 Cr IGSL acquisition (Gurugram focus, NIL FY22-25 turnover) highlights dormant asset plays for residential, no approvals fast-tracks [POSITIVE: Capacity expansion amid urban demand]

Sammaan Capital's AA+/Stable (first in 8 yrs) post-promoter shift contrasts sector downgrades, strong buffers enable growth [BULLISH: Lower funding costs]

Delhivery's 24M share sale (holding -3.21% pts) by Nexus funds over 9 months flags early investor exits, watch for sector conviction [BEARISH: Potential valuation reset]

Adani's ESG 1+ + Sammaan upgrades (2/9 filings) reflect disclosure-driven premiums, outperforming non-rated peers [POSITIVE: Institutional inflows]

Hipolin/Laxmi filings (compliance/ESOP approval) confirm regulatory adherence, reducing delisting risks vs recent IPO volatility [NEUTRAL-POSITIVE: Trading stability]

Monitor completion by Apr15'26 for any delays in ₹1,123 Cr deal, land development updates

Apr28'26 for FY26 results/dividend; watch payout ratio vs historical trends, auto demand guidance

Track creditor meetings (secured/unsecured for Apollo/Healthco/Keimed) post-Mar26 order, scheme approval timeline

Further sales by Nexus post-Apr8'26 12M tranche; monitor holdings below 3.55%, open market pressure

Post-allotment listing steps incl. notifications/fees after Apr10 BSE approval; liquidity impact on scrip 544339

IHC transition completion per Oct'25 agreement; rating stability, funding plans

Any follow-up demat/rejections post-Apr1 cert; scrip 530853 performance

Peer comparisons to '1+' rating; sustainability-linked financing opportunities